Jaguar Animal Health Announces Positive Results in University Pilot Safety Study of Crofelemer in Horses

Study is First Step in Jaguar’s Development Program for a Crofelemer
Drug Product Candidate for Treatment of Diarrhea Associated with Acute
Colitis in Horses

SAN FRANCISCO–(BUSINESS WIRE)–Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an
animal health company focused on developing and commercializing
first-in-class gastrointestinal products for companion and production
animals, and horses, announced positive results today for a pilot safety
study it initiated earlier this month in conjunction with Louisiana
State University to evaluate use of crofelemer in horses. Crofelemer is
an active pharmaceutical ingredient (API) isolated and purified from the Croton
lechleri
tree, which is sustainably harvested.

The study involved three healthy horses treated with three consecutive,
three-day cycles of escalating dose levels (up to approximately eight
times the proposed dosage in horses) of an oral crofelemer paste.
Clinical observations, vital signs, biochemical changes (complete blood
count, serum chemistry and urinalysis) and adverse events were evaluated
for dose-limiting toxicity after each dose level. The study concluded
that dose-limiting toxicities were not observed at any of the three dose
levels.

“The results of this pilot study in horses are consistent with our
findings on the safety of crofelemer in several other species, and
permit us to proceed confidently with our development program in horses.
Part of that development program concerns the use of crofelemer for the
treatment of diarrhea associated with acute colitis,” stated Lisa Conte,
Jaguar’s president and CEO. Colitis is defined as inflammation of the
large bowel, and the condition can affect adult horses as well as foals.
Acute colitis can cause sudden, massive fluid loss and severe
electrolyte imbalances that can result in death. Acute colitis often
occurs when Salmonella and Clostridium difficile, bacteria
that are normally present in the gut, are activated by stress, or when
the rickettsia Neorickettsia risticii is ingested, causing
Potomac Horse Fever, which has been studied as a secretory type of
diarrhea by third parties. Stress (e.g., shipping, changes in daily
routines, illness, hospitalization, surgery, racing), recent diet
changes, recent antimicrobial administration, and non-steroidal
anti-inflammatory drug therapy can also put horses at risk for acute
colitis.

About Jaguar Animal Health, Inc.

Jaguar Animal Health, Inc. is an animal health company focused on
developing and commercializing first-in-class gastrointestinal products
for companion and production animals, and horses. Canalevia
is Jaguar’s lead prescription drug product candidate for the treatment
of various forms of diarrhea in dogs. Canalevia is a
canine-specific formulation of crofelemer, an active pharmaceutical
ingredient isolated and purified from the Croton lechleri tree,
which is sustainably harvested. Neonorm Calf and Neonorm
Foal are the Company’s lead non-drug products. Neonorm is a
standardized botanical extract derived from the Croton lechleri
tree. Canalevia and Neonorm are distinct
products that act at the same last step in a physiological pathway
generally present in mammals. Jaguar has nine active investigational new
animal drug applications, or INADs, filed with the FDA and intends to
develop species-specific formulations of Neonorm in six
additional target species, and formulations of Canalevia for
cats, horses and dogs.

For more information, please visit www.jaguaranimalhealth.com.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking
statements.” These include statements regarding the Company’s intention
to develop species-specific formulations of Neonorm in
additional target species, and the Company’s plan to develop
formulations of Canalevia for cats, horses and dogs. In some
cases, you can identify forward-looking statements by terms such as
“may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,”
“intend,” “target,” “project,” “contemplate,” “believe,” “estimate,”
“predict,” “potential” or “continue” or the negative of these terms or
other similar expressions. The forward-looking statements in this
release are only predictions. Jaguar has based these forward-looking
statements largely on its current expectations and projections about
future events. These forward-looking statements speak only as of the
date of this release and are subject to a number of risks, uncertainties
and assumptions, some of which cannot be predicted or quantified and
some of which are beyond Jaguar’s control. Except as required by
applicable law, Jaguar does not plan to publicly update or revise any
forward-looking statements contained herein, whether as a result of any
new information, future events, changed circumstances or otherwise.

Jaguar-JAGX

Contacts

KCSA Strategic Communications
Garth Russell, 212-896-1250
grussell@kcsa.com
or
Allison
Soss, 212-896-1267
asoss@kcsa.com